Ps962 phase 1 results of zuma-4: kte-x19, an anti-cd19 chimeric antigen receptor t cell therapy, in pediatric and adolescent patients with relapsed/refractory b cell acute lymphoblastic leukemia
HemaSphere（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要